OBJECTIVE To illustrate the generic strategy of doxorubicin liposome®. METHODS Referencing literatures,the development and technical characteristics of Doxil® were reviewed. FDA guidance of the liposome was referred, and combined with experience in research and development, the generic strategy of Doxil® was summarized. RESULTS AND CONCLUSION Generic strategy of liposomes need to analyze the final formulation, process formulation and preparation of Reference list drug (RLD). Using QbD principle to determine the appropriate formulation process conditions. Reasonable quality control and key attributes were determined according to product characteristics, appropriate evaluation methods and standards were established, and overall quality comparison was made between generic drug and RLD. Studies on bioequivalence of liposome drugs in vivo need to compare the pharmacokinetic behavior of free drugs and encapsulated drugs and even metabolite at the same time.
BANGHAM A D, HORNE R W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope[J]. J Mol Biol, 1964, 8(5):660-668.
[2]
GABIZON A, PERETZ I, SULKES A, et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study[J]. Eur J Cancer Clin Oncol, 1989, 25(12):1795-1803.
[3]
BARENHOLZ Y C. Doxil®-The First FDA-Approved Nano-Drug: From an Idea to a Product. Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications, ed[M]. Singapore: Pan Stanford Publishing Pte. Ltd. 2012.
[4]
GABIZON A, CHISIN R, AMSELEM S, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin[J]. Br J Cancer, 1991,64(6):1125-1132.
[5]
BARENHOLZ Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned[J]. J Controlled Release, 2012, 160(2):117-134.
[6]
BARENHOLZ Y. Amphipathic Weak Base Loading into Preformed Liposomes Having a Transmembrane Ammonium Ion Gradient: From the Bench to Approved Doxil. In: Gregoriadis G.(Ed), Liposome Technology, Volame Ⅱ: Edntrapment of Drugs and other Material into Liposomes[M]. Rata Raton:CRC Press,2007.
[7]
BARENHOLZ Y. Liposome application: problems and prospects[J]. Curr Opin Colloid Interface Sci, 2001,6(1):66-77.
[8]
HARAN G. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases[J]. Biochim Biophys Acta, 1993, 1151(2):201-215.
[9]
YECHEZKEL B. Method of amphipathic drug loading in liposomes by pH gradient[P]. US5192549,1993-03-09.
[10]
NICHOLS J W, DEAMER D W. Catecholamine uptake and concentration by liposomes maintaining pH gradients[J].Biochimica et Biophysica Acta (BBA)-Biomembranes, 1976, 455(1):269-271.
[11]
DEAMER D W, PRINCE R C, CROFTS A R. The response of fluorescent amines to pH gradients across liposome membranes[J].Biochimica et Biophysica Acta (BBA)-Biomembranes, 1972, 274(2):323-335.
[12]
MADDEN T D, BALLY M B, HOPE M J, et al. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents[J].Biochimica et Biophysica Acta (BBA)-Biomembranes, 1985, 817(1):67-74.
[13]
HOPE M J, BALLY M B, WEBB G, et al. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1985, 812(1):55-65.
[14]
CULLIS P R, BALLY M B, MADDEN T D, et al. pH Gradients and membrane transport in liposomal systems[J].Trends Biotechnol, 1991, 9(8):268-272.
[15]
STEPHANE C, YECHEZKEL B. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients[J]. Biochimica et Biophysica Acta (BBA), 1995, 1240:257-265.
[16]
VEIRO J A, CULLIS P R. A novel method for the efficient entrapment of calcium in large unilamellar phospholipid vesicles[J]. Biochim Biophys Acta, 1990, 1025(1):109-115.
[17]
GABIZON A, SHIOTA R, PAPAHADJOPOULOS D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times[J]. JNCI J Nat Cancer Inst, 1989, 81(19):1484-1488.
[18]
DRUMMOND D C, NOBLE C O, GUO Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy[J]. Cancer Res, 2006, 66(6):3271-3277.
[19]
ALLEN T M, CHONN A. Large unilamellar liposomes with low uptake into the reticuloendothelial system[J]. FEBS Letters, 1987, 223(1):42-46.
[20]
ALLEN T M. Liposome with enhanced circulation time[P]. US4837028, 1989-06-06.
[21]
GABIZON A, PAPAHADJOPOULOS D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors[J]. Proc Natl Acad Sci USA, 1988, 85(18):6949-6953.
[22]
ABUCHOWSKI A, MCCOY J R, PALCZUK N C, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase[J]. J Biol Chem, 1977, 252(11):3582-3586.
[23]
VERONESE F M, PASUT G. PEGylation, successful approach to drug delivery[J]. Drug Discov Today, 2005, 10(21):1451-1458.
[24]
OLSON F, HUNT C A, SZOKA F C, et al. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1979, 557(1):9-23.
[25]
MAYER L D, BALLY M B, HOPE M J.et al. Techniques for encapsulating bioactive agents into liposomes[J]. Chem Phys Lipids, 1986, 40(2-4):333-345.
[26]
Doxil label. Available from: https:// www. accessdata. fda. Gov/drugsatfda_docs/label/2015/050718 s 046lbl.pdf.
[27]
GABIZON A, SHMEEDA H, BARENHOLZ Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies[J]. Clin Pharmacokinet, 2003, 42(5):419-436.
[28]
JIANG W, LIONBERGER R, YU L X. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin[J]. Bioanalysis, 2011, 3(3):333-344.
[29]
CROMMELIN D, METSELAAR J, STORM G. Liposomes: The Science and the Regulatory Landscape. In: Crommelin D., de Vlieger J. (eds) Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, vol 20[M]. New York:Springer, 2015.
[30]
Draft Guidance on Doxorubicin Hydrochloride [EB/OL] [2019-2-20]: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf.
[31]
XU X, KHAN M A, BURGESS D J. A quality by design (QbD) case study on liposomes containing hydrophilic API:Ⅰ. formulation, processing design and risk assessment[J]. Int J Pharm, 2011, 419(1-2):52-59.
[32]
XU X, KHAN M A, BURGESS D J. A quality by design (QbD) case study on liposomes containing hydrophilic API:Ⅱ. screening of critical variables, and establishment of design space at laboratory scale[J]. Int J Pharm, 2012, 423(2):543-553.
[33]
JOHNSTON M J, EDWARDS K, KARLSSON G, et al. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations[J]. J Liposome Res, 2008, 18(2):145-157.
SAMUNI A M, LIPMAN A, BARENHOLZ Y. Damage to liposomal lipids: protection by antioxidants and cholesterol-mediated dehydration[J]. Chem Phys Lipids, 2000, 105(2):121-134.
[36]
TAKAHASHI N, HIGASHI K, UEDA K, et al. Determination of nonspherical morphology of doxorubicin-loaded liposomes by atomic force microscopy[J]. J Pharm Sci, 2018, 107(2):717-726.
[37]
ALMGREN M, EDWARDS K, KARLSSON G. Cryo transmission electron microscopy of liposomes and related structures[J]. Colloids and Surfaces A: Physicoche Eng Aspec, 2000, 174(1-2):3-21.
[38]
PERETZ DAMARI S, SHAMRAKOV D, VARENIK M, et al. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes[J]. Int J Pharm, 2018, 547(1-2):648-655.
[39]
MIRANDA M. In vitro characterization of liposomal encapsulated doxorubicin using CryoTEM[J]. Controlled Release Society Newsletter, 2013, 30(3):22-24.
[40]
LI X, HIRSH D J, CABRAL-LILLY D, et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient[J]. Biochim Biophys Acta, 1998, 1415(1):23-40.
[41]
ABRAHAM S A, EDWARDS K, KARLSSON G, et al. Formation of transition metal-doxorubicin complexes inside liposomes[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2002, 1565(1):41-54.
[42]
FROHLICH M, BRECHT V, PESCHKA-SUSS R. Parameters influencing the determination of liposome lamellarity by 31P-NMR[J]. Chem Phys Lipids, 2001, 109(1):103-112.
[43]
BERGER N, SACHSE A, BENDER J, et al. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics[J]. Int J Pharm, 2001, 223(1-2):55-68.
[44]
WIBROE P P, AHMADVAND D, OGHABIAN M A, et al. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil(R), Caelyx(R), DOXOrubicin, and SinaDoxosome[J]. J Controlled Release, 2016, 221:1-8.
[45]
DEMETZOS C. Differential scanning calorimetry (DSC):a tool to study the thermal behavior of lipid bilayers and liposomal stability[J]. J Liposome Res, 2008, 18(3):159-173.
[46]
WEI X, COHEN R, BARENHOLZ Y. Insights into composition/structure/function relationships of Doxil(R) gained from "high-sensitivity" differential scanning calorimetry[J]. Eur J Pharm Biopharm, 2016, 104:260-270.
[47]
PIPPA N, PERINELLI D R, PISPAS S, et al. Studying the colloidal behavior of chimeric liposomes by cryo-TEM, micro-differential scanning calorimetry and high-resolution ultrasound spectroscopy[J]. Colloids Surfaces A: Physicochem Eng Aspec, 2018, 555:539-547.
[48]
CLERC S, BARENHOLZ Y. A quantitative model for using acridine orange as a transmembrane pH gradient probe[J]. Anal Biochem, 1998, 259(1):104-111.
[49]
SCHILT Y, BERMAN T, WEI X, et al. Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs[J]. Biochim Biophys Acta, 2016, 1860(1 Pt A):108-119.
[50]
SUBRAMANIAN N, RAYASA M. Use of electrolyte induced flocculation technique for an in vitro steric stability study of steric stabilized liposome formulations[J]. Die Pharm, 2004,59:74-76.
[51]
LIN W, GARNETT M C, SCHACHT E, et al. Preparation and in vitro characterization of HSA-mPEG nanoparticles[J]. Int J Pharm, 1999, 189(2):161-170.
[52]
YUAN W, KUAI R, DAI Z, et al. Development of a flow-through USP-4 apparatus drug release assay to evaluate doxorubicin liposomes[J]. AAPS J, 2017, 19(1):150-160.
[53]
SCHüLLER J, CZEJKA M, BANDAK S, et al. 959 Comparison of pharmacokinetics (PK) of free and liposome encapsulated doxorubicin in advanced cancer patients[J]. Eur J Cancer, 1995, 31:S199.
[54]
CUI J, LI C, GUO W, et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? [J]. J Controlled Release, 2007, 118(2):204-215.
[55]
YAMAMOTO E, HYODO K, OHNISHI N, et al. Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2011, 879(30):3620-3625.
2019, Vol. 54 
